Mehrdad Shamloo | Brain and Behavior | Excellence in Research

🌟Prof. Mehrdad Shamloo, Brain and Behavior, Excellence in ResearchπŸ†

  • Professor at Stanford University, United States

Dr. Mehrdad Shamloo is a distinguished neuroscientist, holding a Ph.D. in Medical Science from the Faculty of Medicine at the University of Lund, Sweden. Currently serving as a Professor of Neurosurgery and Neurology at Stanford University School of Medicine, he has made significant contributions to the fields of neurobiology and pharmacology. With a focus on understanding neurodegenerative diseases like Alzheimer’s and Parkinson’s, Dr. Shamloo’s research endeavors aim to unravel the underlying mechanisms and develop innovative therapeutic interventions. His expertise spans across preclinical studies, translational neuroscience, and behavioral neuroscience.

Author Metrics

Dr. Shamloo’s scholarly impact is reflected in his author metrics, including citation indices, h-index, and publication output. His research findings have garnered widespread recognition within the scientific community, as evidenced by the citation count of his publications and his influence in shaping the discourse in the field of neuroscience.

ORCID Profile

Scopus Profile

Dr. Mehrdad Shamloo is affiliated with Stanford University School of Medicine in Stanford, United States. He can be contacted at 6603067067. His Scopus Author Identifier is 0000-0003-4404-1755, where you can view his ORCID profile.

According to Scopus, Dr. Shamloo has accumulated 6,534 citations from 5,928 documents. He has authored 77 documents, with an h-index of 42. This indicates that 42 of his publications have each been cited at least 42 times.

Education

Dr. Shamloo commenced his academic journey by earning a Bachelor of Science degree from Malmo College of Health and Science, Sweden, in 1994. Subsequently, he pursued a Master of Science in Medical School at the University of Lund, Sweden, graduating in 1998. His academic pursuit culminated in a Ph.D. in Medical Science from the Faculty of Medicine at the University of Lund, Sweden, in 1999.

Research Focus

Dr. Shamloo’s research interests revolve around elucidating the molecular and cellular mechanisms underlying neurodegenerative diseases, particularly Alzheimer’s and Parkinson’s diseases. His investigations span various areas, including the role of gut microbiota in neuroinflammation, modulation of neuronal receptors for cognitive enhancement, and development of novel therapeutic agents targeting neuroimmune pathways.

Professional Journey

Throughout his illustrious career, Dr. Shamloo has held key positions in academia and industry. He served as the Director of the Behavioral and Functional Neuroscience Laboratory at Stanford Neuroscience Institute and has been instrumental in establishing several research programs and institutes dedicated to translational neuroscience. Prior to his academic appointments, Dr. Shamloo held research and leadership roles in pharmaceutical companies, contributing significantly to preclinical drug development.

Honors & Awards

Dr. Shamloo’s contributions to neuroscience have been recognized through numerous prestigious awards and honors. Notably, he has received the AGY Award for his outstanding preclinical studies and dedication to advancing neuroscientific research. His work has also been supported by substantial funding from renowned institutions like the National Institutes of Health (NIH) and the Stanford SPARK program.

Publications Top Noted & Contributions

Dr. Shamloo has made substantial contributions to the scientific literature, with his research findings published in reputable peer-reviewed journals. His publications cover a wide range of topics, including neuropharmacology, neuroinflammation, neurodegenerative diseases, and translational neuroscience. Through his scholarly endeavors, Dr. Shamloo has significantly enriched our understanding of the pathophysiology of neurological disorders and has paved the way for the development of novel therapeutic strategies.

1. Locus Coeruleus and Noradrenergic Pharmacology in Neurodegenerative Disease

  • Year: 2023
  • Type: Book Chapter
  • DOI: 10.1007/164_2023_677
  • Contributors: Rachel A. Matt; Renee S. Martin; Andrew K. Evans; Joel R. Gever; Gabriel A. Vargas; Mehrdad Shamloo; Anthony P. Ford

2. Schwann Cells Promote Sensory Neuron Excitability During Development

  • Year: 2023
  • Type: Other
  • DOI: 10.2139/ssrn.4405268
  • EID: 2-s2.0-85151873672
  • Contributors: Kantarci, H.; Elvira, P.D.; Thottumkara, A.P.; Iyer, M.; Donovan, L.J.; Dugan, M.Q.; Ambiel, N.; O’Connell, E.M.; Granados, A.; Zeng, H. et al.

3. The anti-inflammatory effects of photobiomodulation are mediated by cytokines: Evidence from a mouse model of inflammation

  • Year: 2023
  • Type: Journal Article
  • DOI: 10.3389/fnins.2023.1150156
  • EID: 2-s2.0-85153495213
  • Contributors: Shamloo, S.; Defensor, E.; Ciari, P.; Ogawa, G.; Vidano, L.; Lin, J.S.; Fortkort, J.A.; Shamloo, M.; Barron, A.E.

4. Beta-2 adrenergic receptor agonism alters astrocyte phagocytic activity and has potential applications to psychiatric disease

  • Year: 2022
  • Type: Other
  • DOI: 10.21203/rs.3.rs-2086278
  • EID: 2-s2.0-85142407241
  • Contributors: Wilson, J.; Bowen, E.; DiGiacomo, P.; Fraser, H.; Guttenplan, K.; Smith, B.; Heberling, M.; Vidano, L.; Shamloo, M.; Shah, N. et al.

5. Brain-Wide Cellular Resolution Regional Quantification of Microglia and Amyloid in 5xFAD mice

  • Year: 2022
  • Type: Journal Article
  • DOI: 10.1002/alz.066431
  • EID: 2-s2.0-85144410156
  • Contributors: Guanzon, N.; Murry, A.; May, E.; Wells, A.; Gallegos, Y.; Redd, C.; Azevedo, R.; Shamloo, M.; Gandho, S.; Wheeler, D.G.

Research Timeline

Dr. Shamloo’s research trajectory spans over several decades, encompassing various research projects, collaborations, and academic appointments. Beginning with his doctoral studies in the late 1990s, he has continually advanced his research agenda, securing funding, publishing prolifically, and making significant contributions to both basic and translational neuroscience. His research timeline underscores his commitment to advancing scientific knowledge and addressing pressing challenges in neurodegenerative diseases.